|
Lesion
|
Cases attributable to HPV 6/11/16/18 and associated costs
|
Cases attributable to HPV 6/11/16/18/31/33/45/52/58 and associated costs
|
Cases attributable to HPV 31/33/45/52/58 and associated costs (a)
|
|---|
|
Number of annual cases
|
Costs (€ 2017)
|
Number of annual cases
|
Costs (€ 2017)
|
Number of annual cases
|
Costs (€ 2017)
|
|---|
|
Genital warts (b)
|
49,251
|
51.04 Mill €
|
49,251
|
51.04 Mill €
|
0
|
0.00 Mill €
|
|
CIN 2/3
|
15,285
|
35.50 Mill €
|
27,648
|
64.22 Mill €
|
12,363
|
28.72 Mill €
|
|
VIN2/3
|
1001
|
3.93 Mill €
|
1162
|
4.56 Mill €
|
161
|
0.63 Mill €
|
|
VaIN 2/3
|
155
|
0.55 Mill €
|
186
|
0.66 Mill €
|
31
|
0.11 Mill €
|
|
AIN 2/3 (b)
|
149
|
0.59 Mill €
|
162
|
0.65 Mill €
|
13
|
0.05 Mill €
|
|
PIN 2/3
|
218
|
0.59 Mill €
|
247
|
0.67 Mill €
|
29
|
0.08 Mill €
|
|
Cervical cancer (c)
|
1730
|
15.15 Mill €
|
2110
|
18.48 Mill €
|
380
|
3.33 Mill €
|
|
Vulvar cancer (d)
|
94
|
1.22 Mill €
|
110
|
1.43 Mill €
|
16
|
0.21 Mill €
|
|
Vaginal cancer (c)
|
50
|
0.54 Mill €
|
66
|
0.71 Mill €
|
16
|
0.17 Mill €
|
|
Anal cancer (b)(c)(e)
|
264
|
2.02 Mill €
|
289
|
2.21 Mill €
|
25
|
0.19 Mill €
|
|
Penile cancer (c)(e)
|
98
|
0.70 Mill €
|
111
|
0.79 Mill €
|
13
|
0.09 Mill €
|
|
Oral cavity (b)(c)(e)
|
131
|
1.03 Mill €
|
147
|
1.15 Mill €
|
16
|
0.12 Mill €
|
|
Nasopharynx (b)(c)(e)
|
27
|
0.21 Mill €
|
32
|
0.25 Mill €
|
5
|
0.04 Mill €
|
|
Oropharynx cancer (b)(c)(e)
|
258
|
1.94 Mill €
|
272
|
2.05 Mill €
|
14
|
0.10 Mill €
|
|
Hypopharynx (b)(c)(e)
|
28
|
0.23 Mill €
|
34
|
0.28 Mill €
|
6
|
0.05 Mill €
|
|
Pharynx cancer (b)(c)(e)
|
39
|
0.30 Mill €
|
39
|
0.30 Mill €
|
0
|
0.00 Mill €
|
|
Larynx cancer (b)(c)(e)
|
132
|
1.15 Mill €
|
171
|
1.49 Mill €
|
39
|
0.34 Mill €
|
|
TOTAL
|
68,910
|
116.7 Mill €
|
82,038
|
150.9 Mill €
|
13,128
|
34.24 Mill €
|
- (a) Difference between the number of cases of each lesion attributable to the genotypes targeted by the 9-valent and 4-valent vaccines and associated costs
- (b) Includes both men and women
- (c) Genotypes 6 and 11 not included
- (d) HPV attributable fraction estimated on HPV DNA and p16 positivity
- (e) Only hospitalization costs were considered
- AIN anal intraepithelial neoplasia; CIN cervical intraepithelial neoplasia; HPV human papillomavirus; mill.: million; PIN penile intraepithelial neoplasia; VaIN vaginal intraepithelial neoplasia; VIN vulvar intraepithelial neoplasia
